NEW YORK (GenomeWeb) – Foundation Medicine and Incyte have partnered to develop and commercialize companion diagnostics, the companies said today.

The initial focus will be on developing a CDx for Incyte's FGFR1/2/3 inhibitor, pemigatinib, to treat patients with cholangiocarcinoma. This will include the detection of activating FGFR2 translocations. The companies expect to incorporate the CDx into Foundation Medicine's existing US Food and Drug Administration-approved assay, FoundationOne CDx.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec
04
Sponsored by
Sophia Genetics

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Dec
06

Rhythm Pharmaceuticals and Genomenon will discuss their efforts to assemble a database of mutations associated with rare genetic disorders of obesity, and how this was optimized to facilitate a deep understanding of the variant landscape of melanocortin-4 receptor (MC4R)-pathway genes. This database may help identify MC4R-pathway deficient individuals who might benefit from future precision therapies.